Kraig Biocraft Laboratories Inc (KBLB)

[Deannie]

Read the news and while I understand the expectation that funds will expand production (a good thing assuming the $$$ is just a loan and not part of further dilution), it also suggests they don’t expect production in the short/medium term to cover costs and other expenses. I’ve always feared genetic drift has been to blame for production woes since 10/2020 and until I see proof otherwise, that’s still my #1 concern for the stock in the short and medium term.

Many cite the RS as weighing down the stock. I never felt that way as it’s just a simple, transparent increase in the sp via reducing the number of outstanding shares to satisfy a NASDAQ sp requirement and nothing more. Some suggest Kim expects to achieve a $5 (or so) share price organically, which, if he in fact still wants to go to NASDAQ is a good thing. However, the KBLB pessimist in me (nurtured by Kim’s actions/lack of production these past three years) thinks there’s a chance he doesn’t want the scrutiny and stricter regulations NASDAQ requires (which would be bad). While I’m ultimately glad Kim abandoned the RS idea, it’s only because many perceived it as a boat anchor weighing down the sp, which, if people believe their convictions, should spur strong volume in the millions (plural) tomorrow with a close well above $.10. If we don’t see that, it’ll say to me that the RS meant little despite the grumbling over it on this board. As for the patent stuff, it feels good but is secondary to production, at least for now. We’ll see what tomorrow brings.